drugset / Trial / NCT00648492

Food Study Metformin Hydrochloride ER Tablets 500 mg and Glucophage® XR 500 mg

NCT00648492 ↗

Phase 1 Completed 18 enrolled Mylan Pharmaceuticals Inc
RandomizedCrossoverOpen-labelOther

Summary

The objective of this study is to investigate the bioequivalence of Mylan's metformin hydrochloride ER tablets to Bristol-Myers Squibb's Glucophage® XR tablets following a single, oral 500 mg (1 x 500 mg) dose administered under fed conditions.

Timeline

Start
2002-10
Primary completion
2002-11
Completion
2002-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Metformin Small molecule 500 mg Oral

Indications

No indication recorded.